• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Sunday 07/22/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

autoimmune

  • 2:26 PM

    ORLANDO, Fla., April 27, 2016, IMUN, (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTCQB:IMUN) (the “Company”), a clinical-stage biotech company providing immunotherapy solutions for the treatment of autoimmune disease and cancer with a focus on emerging nations, today announced that Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has approved its patented Lodonal as an over the counter, non-toxic adjunct therapy in the treatment of HIV/AIDS and immune system regulator. The receipt of NAFDAC’s approval will enable the

    Read more
  • 4:14 PM

    Company Also Announced the Submission of Lodonal(TM) Data for Review in Connection with the New Drug Application to NAFDAC for Use as an Immune Booster and Adjunct Treatment for Human Immunodeficiency Virus ORLANDO, FL, IMUN, / ACCESSWIRE / Immune Therapeutics Inc., a U.S. public company (OTCQB: IMUN) today announced that it has completed its 90-day bridging trail of Human Immunodeficiency Virus positive [HIV+] patients and submitted data to The National Agency for Food and Drug Administration and Control, (NAFDAC) in

    Read more
Public Wire Banner